Biopharmaceutical company PureTech Health plc (LSE: PRTC) reported on Wednesday the appointment of Dr Susan Dillon as an independent member to the board of Vedanta Biosciences.

Vedanta is a clinical-stage company that was founded by PureTech.

Dr Dillon brings extensive drug development experience in immunology and infectious disease, having led the approvals and expansions of several blockbuster products.

She is co-founder, president and CEO of biotechnology company Aro Biotherapeutics and previously served as global therapeutic area head for immunology at Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). During her 16 years at Janssen, Dr Dillon led biologics discovery and global immunology R&D teams that were responsible for achieving numerous regulatory approvals for innovative antibody products for autoimmune diseases.

Dr Dillon also currently serves on the board of directors of the Wistar Institute and is an advisor to the DMAX Foundation, which focuses on mental health.